Analysis

Mid-day market update: Nasdaq dips 250 points, TherapeuticsMD shares surge

Midway through trading Tuesday, the Dow traded up 0.66% to 36,827.65 while the NASDAQ fell 1.63% to 15,574.50. The S&P also fell, dropping 0.08% to 4,792.93.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 57,131,180 cases with around 848,880 deaths. India confirmed a total of at least 34,960,260 cases and 482,010 deaths, while Brazil reported over 22,305,070 COVID-19 cases with 619,240 deaths. In total, there were at least 293,085,990 cases of COVID-19 worldwide with more than 5,467,810 deaths.

Leading and Lagging Sectors

Energy shares climbed 3.7% on Tuesday. Meanwhile, top gainers in the sector included NexTier Oilfield Solutions Inc. NEX +26.49% (Get Free Alerts for NEX), up 24% and Centennial Resource Development, Inc. CDEV +9.53% (Get Free Alerts for CDEV) up 9%.

In trading on Tuesday, information technology shares fell 1.5%.

Top Headline

The ISM manufacturing PMI dropped to 58.7 in December from 61.1 in the previous month. However, analysts were expecting a reading of 60.

Equities Trading UP

Oragenics, Inc. OGEN +16.24% shares shot up 18% to $0.5575. The company reported in Form 4 filing that Director Robert Koski bought 1 million shares at an average price of $0.47 per share.

Shares of NexTier Oilfield Solutions Inc. NEX +26.49% got a boost, shooting 24% to $4.79 after the company issued an operational update and guidance for the fourth quarter. The company said it expects Q4 revenue of $500-$510 million, reflecting a surge of more than 25% from Q3 2021.

TherapeuticsMD, Inc. TXMD +24.57% shares were also up, gaining 31% to $0.5150 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.

Equities Trading DOWN

AVROBIO, Inc. AVRO -32.67% shares tumbled 34% to $2.6650 after the company reported it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024. It is deprioritizing its Fabry disease program.

Shares of iCAD, Inc. ICAD -21.79% were down 22% to $5.89 after the company issued Q4 and FY21 sales guidance below estimates.

Gritstone bio, Inc. GRTS -34.58% was down, falling 35% to $7.97 as the company shared data from the first cohort (10 µg dose) of the Phase 1 booster trial of self-amplifying mRNA (samRNA) COVID-19 vaccine.

Commodities

In commodity news, oil traded up 1.2% to $77.01, while gold traded up 0.7% to $1,812.50.

Silver traded up 0.8% Tuesday to $22.995 while copper rose 0.5% to $4.4440.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 climbed 0.82%, London’s FTSE 100 jumped 1.63%, while Spain’s IBEX 35 Index gained 0.39%. The German DAX gained 0.82%, French CAC 40 surged 1.39% and Italy’s FTSE MIB Index gained 0.81%.

The IHS Markit/CIPS UK manufacturing PMI increased to 57.9 in December from a preliminary reading of 57.6, while consumer credit rose by GBP 1.2 billion in November. The annual inflation rate in France came in steady at 2.8% year-over-year in December.

The unemployment rate in Germany fell to 5.2% in December from 5.3% in the prior month, while retail sales in Germany rose 0.6% in November. The number of people registered as unemployed in Spain fell 76,782 from a month ago to 3.106 million in December.

Economics

The ISM manufacturing PMI dropped to 58.7 in December from 61.1 in the previous month. However, analysts were expecting a reading of 60.

US job openings dropped to 10.6 million in November, from 11.1 million in the earlier month, the Labor Department said.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.